PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer
Details
Publication Year 2023-04-03,Volume 220,Issue #4,Page e20220729
Journal Title
Journal of Experimental Medicine
Publication Type
Research article
Abstract
We performed single-cell RNA-sequencing and T cell receptor clonotype tracking of breast and ovarian cancer patients treated with the CDK4/6 inhibitor ribociclib and PD-1 blockade. We highlight evidence of two orthogonal treatment-associated phenomena: expansion of T cell effector populations and promotion of T cell memory formation. Augmentation of the antitumor memory pool by ribociclib boosts the efficacy of subsequent PD-1 blockade in mouse models of melanoma and breast cancer, pointing toward sequential therapy as a potentially safe and synergistic strategy in patients.
Publisher
Rockefeller University Press
Keywords
Animals; Mice; *Programmed Cell Death 1 Receptor; Aminopyridines/pharmacology; Purines; *Melanoma
Department(s)
Laboratory Research
PubMed ID
36688919
Open Access at Publisher's Site
https://doi.org/10.1084/jem.20220729
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-07-18 07:52:26
Last Modified: 2023-07-18 07:52:55

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙